Sign In
Buy SDZNY
$79.34
-0.468 (-0.586%)
At Close: Jun 03, 2026
Novartis After Sandoz: The Business Without Generics
06:38am, Sunday, 06'th Apr 2025
Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology, and neurolo
MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz b
Sandoz: Upgrading To A Buy On 2028 Expectations
01:16pm, Friday, 28'th Mar 2025
Upgraded Sandoz from "hold" to "buy on dips" due to strong cash flow, promising growth in generics, and mid-term EBITDA margin guidance of 24-26% by 2028. Sandoz's 2024 revenue grew 4%, with a core EB
Sandoz signs landmark supply and manufacturing agreement
10:38am, Tuesday, 18'th Mar 2025
BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp
Sandoz reports strong FY 2024 results and Q4 2024 sales
12:59am, Wednesday, 05'th Mar 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.
Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
05:00pm, Monday, 03'rd Mar 2025
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upf
Sandoz family foundation offers $3 billion worth of Novartis shares
01:55pm, Tuesday, 25'th Feb 2025
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
01:00am, Monday, 24'th Feb 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars
Francisco Ballester to retire; Peter Stenico appointed President Region International
01:00am, Monday, 03'rd Feb 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, cu
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
12:46pm, Wednesday, 22'nd Jan 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors w
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
01:00am, Tuesday, 14'th Jan 2025
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars Leading in home market Eur
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
06:30am, Friday, 10'th Jan 2025
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ce
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
12:46pm, Monday, 06'th Jan 2025
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for t
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 20'th Dec 2024
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks offers value investors a b
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Monday, 16'th Dec 2024
Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
